| Date | Title | Description |
| 10.08.2026 | Expedition Therapeutics Closes $115 Million Series B |
SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B f... |
| 09.08.2026 | Expedition Therapeutics Lands $115M Series B |
SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round.
>> Click here for more funding data on Expedition Therapeutics
>> To export Expedition Therapeutic... |
| 05.08.2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing.
The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| 16.07.2026 | OMAN'S US$5.2 BILLION FUTURE FUND UNVEILS US$1.744 BILLION IN PROJECTS | MUSCAT, Oman, July 16, 2026 /PRNewswire/ -- Future Fund Oman (FFO), a portfolio of Oman Investment Authority (OIA), the Sultanate of Oman's sovereign wealth fund, has announced a new package of 105 strategic projects and investments worth U... |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding.
The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 19.05.2026 | Full-Life Technologies: $150 Million Financing To Advance Clinical-Stage Radiotherapeutics Pipeline And Manufacturing Capabilities | Full-Life Technologies announced the completion of a US$150 million financing package comprised of approximately US$110 million in Series D equity financing and US$40 million in debt financing. The financing round was led by Vivo Capital an... |
| 13.05.2026 | Antibody discovery platform Immunocan closes RMB250 million Series A | Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi Family Office and follow-on backing from existing investors including Kingray Capital and TigerYeah Capital. Th... |
| 09.03.2026 | AN2 Therapeutics: $40 Million Private Placement Financing Announced | AN2 Therapeutics announced that it has entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before deducting placement agent fees and other expenses. The finan... |
| 23.02.2026 | Sensei Biotherapeutics Acquires Faeth Therapeutics And Raises $200 Million In Private Placement | Sensei Biotherapeutics announced it has acquired Faeth Therapeutics and secured approximately $200 million in gross proceeds through a concurrent private placement, positioning the combined company to advance its oncology pipeline through k... |
| 18.02.2026 | Sensei Biotherapeutics Acquires Faeth Therapeutics | Sensei Biotherapeutics (Nansdaq: SNSE), a Boston, MA-based provider of cancer therapeutics, acquired Faeth Therapeutics, a Boston, MA-based provider of multi-node therapies targeting tumor metabolism and signaling.
The amount of the transac... |
| 22.01.2026 | Global healthcare investor Vivo Capital raises $717m so far for tenth PE Fund | - |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases | EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
Mon, Jan 12, 2026 13:00 CET Report this content
EQT Life Sciences invests in U.S.-based Kinaset Thera... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding.
The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma | Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 08.01.2026 | EpiBiologics Closes $107M Series B Funding | EpiBiologics, a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, raised $107M in Series B funding.
The round was co-led by GV (Google Ventures) and Johnson & Johnson, through its corpo... |
| 16.12.2025 | BlossomHill Therapeutics Raises $84M in Series B Extension Funding | BlossomHill Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company, raised $84M in Series B extension funding.
The round was led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, and participati... |
| 05.09.2025 | Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy | SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. T... |
| 15.05.2025 | Vivo Capital: Public Fund Closed With Over $740 Million In Commitments | Vivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund... |
| 07.05.2025 | Vivo Capital closes on $740m for third cycle of evergreen public fund | - |
| 19.10.2024 | Agrolend Secures $53 Million to Fuel Agribusiness Growth in Brazil | In the heart of Brazil's agribusiness landscape, a digital bank is making waves. Agrolend, based in São Paulo, has successfully raised $53 million in a Series C funding round. This latest influx of capital brings the company’s total funding... |
| 18.10.2024 | Agrifintech Agrolend banks $53m Series C: ‘It demonstrates the market’s confidence in our business model’ | Agribusiness finance platform Agrolend has raised a $53 million Series C round, bringing its total funding to nearly $100 million.
Impact investor Creation Investments and Syngenta Group Ventures led the round.
New investors Vivo Ventures, ... |
| 22.09.2024 | Serán Bioscience: $200 Million Strategic Growth Transaction Raised | Serán Bioscience, a leading contract development and manufacturing organization (CDMO) providing a comprehensive suite of development, analytical and manufacturing services to pharmaceutical and biotechnology companies, announced a strategi... |
| 20.03.2024 | Startup Lands $150M for Delicate Dance Between Cancer Cells & Immune Cells | Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, bringing both of them together to spark a thera... |
| 07.11.2022 | Vivo Capital Invests in Zenas Biopharma’s $118 Million Financing to Advance the Company’s Broad Pipeline of Autoimmune Disease Therapeutics | - |
| 08.12.2021 | Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital | - |
| 08.12.2021 | Vivo Capital, Leads a $200m Series A Round of Financing in Avistone Pharmaceuticals | - |
| 30.11.2021 | Vivo Capital, Co-Leads a $75m Series A Round of Financing in Ablaze Pharmaceuticals | - |
| 19.10.2021 | Vivo Leads a $32mm Series A Financing in HistoWiz | - |
| 27.05.2021 | Scientia Raises $50M Growth Equity Investment from Vivo Capital | Scientia Vascular (“Scientia” or the “Company”), a rapidly growing commercial company focused on helping save patients’ lives with a suite of interventional medical devices, has raised $50M of growth equity financing from Vivo Capital, a Pa... |
| 27.05.2021 | Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings | SINGAPORE, May 27, 2021 /PRNewswire/ -- Esco Lifesciences ("Esco", the "Company") announced today the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Nov... |
| 27.05.2021 | Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings | SINGAPORE, May 26, 2021 /PRNewswire/ -- Esco Lifesciences ("Esco", the "Company") announced today the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Nov... |
| 26.05.2021 | Esco Lifesciences Closes a Record-Setting $200M Series A Round Led by Vivo Capital | - |
| 26.05.2021 | Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings | |
| 17.05.2021 | Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals | - |
| 06.05.2021 | Aerobiotix Raises $25M Growth Equity Financing Led by Vivo Capital | - |
| 28.04.2021 | Vivo Invests in Sera Prognostics’ $100 Million Series E Financing | - |
| 24.02.2021 | Provivi raises $10m from Gates Foundation to bring insect pheromone tech to smallholder farmers | The fall armyworm is considered by many to be the most destructive and costly pest that farmers battle around the globe, especially for smallholder farmers. With limited access to inputs or a lack of financial means to purchase the right pr... |
| 09.10.2020 | Neocis bagged US$72m funds by Vivo Capital and DFJ Growth | - |
| 15.07.2020 | Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital | - |
| 15.07.2020 | Preventice Solutions : Announces $137 Million Series B Financing Led by Vivo Capital | MINNEAPOLIS, July 15, 2020 /PRNewswire/ -- Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $... |
| 21.11.2019 | Chinese gene testing firm Genetron snags $71m from Vivo Capital, others | Premium
Beijing-based Genetron, that employs gene detection for cancer treatment, has completed a new funding round at over 500 million yuan ($71 million), per its announcement.
Continue reading this story with a subscription to DealStreetA... |
| 30.10.2019 | Vivo Capital Closes $1.43 Billion Fund IX to Invest in Healthcare and Life Science Companies | - |
| 19.08.2019 | Vivo Capital Raises $1.3 Billion For Ninth Fund | According to an SEC filing, Vivo Capital has raised more than $1.3 billion for its ninth fund called Vivo Capital Fund IX, L.P.
In an SEC filing, it was revealed that Vivo Capital raised more than $1.3 billion for its ninth fund called Vivo... |
| 06.06.2019 | Vivo Capital raises $1.28b for ninth healthcare fund, to invest across US, China | Premium
Vivo Capital, which invests in healthcare companies across the US and Greater China, has amassed $1.28 billion for its ninth private equity fund from 36 investors, according to its latest regulatory filing.
Continue reading this sto... |
| 05.06.2019 | Venture Capitalists Weigh In on the SEC-Kik Case: Term Sheet | THE SEC STRIKES
It’s been a while since I wrote about the state of the cryptocurrency market (largely because many of the private equity-focused Term Sheet readers revolted and urged me to write about “real businesses” instead…).
Paid Conte... |
| 04.03.2019 | MacuLogix Raises $38.7M in Series D Financing Led by Vivo Capital | MacuLogix, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), today announced it completed a Series ... |
| 10.12.2018 | Term Sheet — Monday, December 10 | KLEINER SHAKE-UP
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Feng, who was previously the chief technology officer at Flipboard and Hulu, has been with the firm since 2015. In a Medium po... |
| 13.09.2018 | Term Sheet — Thursday, September 13 | A SUMMER OF PROMOTIONS
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
In January, BoxGroup promoted Nimi Katragadda to partner. In May, Bain Capital Ventures hired Sarah Smith as a ge... |
| 12.09.2018 | Vivo Capital bags $635M for its new biotech public company fund | Vivo Capital has raised a whopping $635 million for a new biotech public company fund — pretty much perfect timing for an investment group with deep roots in the transpacific region and a big interest in IPOs and both smal... |
| 12.09.2018 | Vivo Capital Closes $635M Healthcare Fund | Vivo Capital, a healthcare investment firm with offices in Palo Alto, Beijing, Shanghai, and Taipei, closed Vivo Opportunity Fund, L.P., at $635m.
Investors include financial institutions, pension funds, endowments, foundations, and family ... |
| 11.09.2018 | Vivo Capital Closes Oversubscribed $635 Million Fund to Invest in Public Healthcare Equities | - |
| 09.02.2018 | Healthcare investment firm Vivo Capital leads $55m round in Beijing Innocare | Premium
Healthcare investment firm Vivo Capital has led the $55-million funding round of Beijing Innocare, a biopharmaceutical company that develops treatment for cancer and autoimmune diseases, with CCB Capital also backing the round.
Cont... |
| 18.07.2017 | F-Prime Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
| 18.07.2017 | Rock Springs Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
| 11.06.2017 | Platelet Biogenesis Raises $10M Series A | Platelet BioGenesis, a biotech startup developing a process to produce life-saving human platelets from stem cells for therapeutic applications, announced it has successfully raised $10 million in Series A financing. The round was led by Qi... |
| 08.06.2017 | Harvard University spinout raises $10M to advance platelet bioreactor technology | The new financing will support preclinical studies for Platelet BioGenesis’ stem cell-based bioreactors. The company hopes to begin clinical trials in around three years. By removing human donations from the platelet equation, Platelet Biog... |
| 03.12.2016 | Impel NeuroPharma raises $36M for drug delivery platform that bypasses blood-brain barrier | Impel NeuroPharma co-founder and CEO John Hoekman. (Impel NeuroPharma Photo)
Impel NeuroPharma, a Seattle-based biotechnology and pharmaceutical company, announced a $36 million Series C round to develop neurological drugs and an accompanyi... |
| 27.07.2016 | Tricida raises $55M to prep trials, commercial path for kidney drug | Tricida declined to comment about the funding beyond its news release, which said that the capital will be used to finance late-stage clinical trials of its lead drug candidate, TRC101.
Tricida is currently evaluating its compound in 100 pa... |
| 13.06.2016 | Global Healthcare Investment Firm Vivo Capital Closes VC Fund, at over $100M | Vivo Capital, a global healthcare investment firm, closed a new fund, at over $100m.
Investors in The Vivo PANDA Fund include financial institutions, corporate entities, and family offices.
The fund plans to invest the capital in innovative... |
| 13.06.2016 | Vivo Capital Closes First Healthcare Venture Capital Focused Fund at Over $100 Million | - |
| 26.05.2016 | Vivo Capital raises $100m for new Sino-healthcare VC fund | Premium
Healthcare investor Vivo Capital has raised up to $100 million for its newly-formed Sino-US venture capital fund.
Continue reading this story with a subscription to DealStreetAsia.
Subscribe
Already a subscriber? Log in
Contact us f... |
| 17.03.2015 | Vivo Capital Closes Oversubscribed $750 Million 8th Fund to Invest in Healthcare in the U.S. and Greater China | - |
| 12.12.2012 | River Vision Development Completes $17M Series A Financing | River Vision Development Corp., a company that develops a novel protein therapy for the treatment of Graves’ Orbitopathy (GO), completed a $17m Series A financing.
The round was led by SR One and Lundbeckfond Ventures with participation fro... |
| 03.01.2012 | Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China | - |
| - | Harvard University spinout raises $10M to advance platelet bioreactor technology | Platelet BioGenesis’ bioreactor
Boston-based Platelet BioGenesis has received $10 million in Series A financing to move their platelet manufacturing technology forward. The financing round for the Harvard University spinout was led by Qimin... |
| - | Tricida raises $55M to prep trials, commercial path for kidney drug | Patients who have chronic kidney disease face permanent kidney damage and the prospect of end-stage renal failure. Clinical-stage drug developer Tricida is trying to bring patients who suffer from this condition a new treatment and it now h... |
